Download Files:
Products Details
Product Description
– FNDR-20123 free base is a safe, first-in-class, and orally active anti-malarial HDAC inhibitor with IC50s of 31 nM and 3 nM for Plasmodium and human HDAC, respectively. FNDR-20123 free base exerts anti-malarial activity against Plasmodium falciparum asexual stage (IC50=41 nM) and sexual blood stage (IC50=190 nM for male gametocytes). FNDR-20123 free base inhibits HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 (IC50=25, 29, 2, 11, and 282 nM, respectively) and inhibits Class III HDAC isoforms at nanomolar concentrations[1].
Web ID
– HY-131708
Shipping
– Room temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C21H23N5O2
References
– [1]Potluri V, et al. Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. Malar J. 2020;19(1):365. Published 2020 Oct 12.
CAS Number
– 1267502-34-0
Molecular Weight
– 377.44
SMILES
– O=C(NO)C1=CC=C(CN2N=NC(C3=CC=C(CN4CCCC4)C=C3)=C2)C=C1
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– DMSO : 35.71 mg/mL (ultrasonic)
Target
– HDAC;Parasite
Isoform
– HDAC;HDAC1;HDAC2;HDAC3;HDAC6;HDAC8;Plasmodium
Pathway
– Anti-infection;Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
